Trinity Biotech (TRIB) shares jumped 50% in recent Tuesday trading after the company said the latest pre-pivotal clinical trial for its continuous glucose monitoring technology yielded "breakthrough" results.
The modular device, described as "disruptively affordable and user-friendly," offers better signal quality and sensor performance, and a 25% to 30% enhancement in the key accuracy indicator compared with other previously released Waveform CGM sensors, the company said Tuesday in a statement.
The trial, which involved 30 diabetic participants, also showed that the patented device's low blood sugar reading accuracy achieved parity with industry benchmarks, the company said.
The company expects to complete further clinical trials for device enhancements and is scheduled to file for regulatory approval in the EU this year and in the US in 2026.
Price: 1.14, Change: +0.38, Percent Change: +50.13
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。